BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

WuXi XDC and HKSTP promote development of bioconjugate drug industry in Hong Kong

October 19, 2023 | News

HKSTP Park companies will leverage WuXi XDC's one-stop service platform to develop ADC and other bioconjugates



WuXi XDC, a China-based Contract, Research, Development, Manufacturing Organisation (CRDMO) focused on the antibody drug conjugate (ADC) and broader bioconjugate market, and Hong Kong Science and Technology Parks Corporation (HKSTP), have signed a collaboration agreement to jointly advance the establishment of a CRDMO value chain in Hong Kong .

The partnership will drive the development of ADC and other bioconjugates in Hong Kong leveraging WuXi XDC's comprehensive services and capabilities. With the aim of boosting the biotechnology ecosystem in Hong Kong, both parties will enhance collaborations among industry, academic and research institutions.

HKSTP Park companies will have access to WuXi XDC's integrated, one-stop bioconjugate platform for drug discovery, development, and analytical services. WuXi XDC will provide consultation and training to Hong Kong biotechnology companies and research institutions, accelerating the translation of the scientific research results into market-ready products.

HKSTPC and WuXi XDC will deepen the collaborations by sharing resources and organizing engagement activities. A roadmap will be set out for propelling the establishment of a CRDMO value chain in Hong Kong, which will in turn speed up the drug development process and shorten the time to market.